KR102412997B1 - 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 - Google Patents

특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 Download PDF

Info

Publication number
KR102412997B1
KR102412997B1 KR1020187009381A KR20187009381A KR102412997B1 KR 102412997 B1 KR102412997 B1 KR 102412997B1 KR 1020187009381 A KR1020187009381 A KR 1020187009381A KR 20187009381 A KR20187009381 A KR 20187009381A KR 102412997 B1 KR102412997 B1 KR 102412997B1
Authority
KR
South Korea
Prior art keywords
subject
pharmaceutical composition
apoe4
mmse
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187009381A
Other languages
English (en)
Korean (ko)
Other versions
KR20180051561A (ko
Inventor
수잔 아부샤크라
에이단 파워
마틴 톨라
존 헤이
제레미 유
페트르 코시스
Original Assignee
알제온, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102412997(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알제온, 인크. filed Critical 알제온, 인크.
Priority to KR1020227009418A priority Critical patent/KR102547164B1/ko
Publication of KR20180051561A publication Critical patent/KR20180051561A/ko
Application granted granted Critical
Publication of KR102412997B1 publication Critical patent/KR102412997B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187009381A 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 Active KR102412997B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227009418A KR102547164B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227009418A Division KR102547164B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20180051561A KR20180051561A (ko) 2018-05-16
KR102412997B1 true KR102412997B1 (ko) 2022-06-23

Family

ID=58240195

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187009381A Active KR102412997B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
KR1020227009418A Active KR102547164B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227009418A Active KR102547164B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102412997B1 (enExample)
CN (3) CN116712423A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4289820A3 (en) 2014-03-21 2024-03-13 Alzheon, Inc. Compounds for use in treating alzheimer's disease in apoe4+/+ patients
JP6789579B2 (ja) * 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
US12285400B2 (en) * 2018-08-01 2025-04-29 Alzheon, Inc. Sulfopropanoic acid derivatives for treating neurodegenerative disorders
DK3829563T3 (en) * 2018-08-01 2025-02-24 Alzheon Inc 3-sulfopropanoic acid for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CA3144008A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
JP2024542844A (ja) * 2021-12-09 2024-11-15 アルツェオン・インコーポレーテッド アルツハイマー病の処置に使用されるａｌｚ－８０１
US20250127734A1 (en) * 2022-02-07 2025-04-24 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071468A1 (en) 2010-08-19 2012-03-22 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
US20140220122A1 (en) 2006-10-12 2014-08-07 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
FI951701L (fi) 1992-10-13 1995-04-10 Univ Duke Menetelmät Alzheimerin taudin tunnistamiseksi
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
CN1867795B (zh) 2003-08-11 2010-12-08 加州理工学院 微流体的大规模集成
WO2007069073A2 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
BRPI0719379A2 (pt) 2006-11-24 2014-02-11 Ac Immune Sa Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
AU2014262890B2 (en) 2013-05-06 2019-01-31 Takeda Pharmaceutical Company Limited Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
NZ723884A (en) * 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
EP4289820A3 (en) * 2014-03-21 2024-03-13 Alzheon, Inc. Compounds for use in treating alzheimer's disease in apoe4+/+ patients
JP6789579B2 (ja) * 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220122A1 (en) 2006-10-12 2014-08-07 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US20120071468A1 (en) 2010-08-19 2012-03-22 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders

Also Published As

Publication number Publication date
JP2022145949A (ja) 2022-10-04
EP4275750A2 (en) 2023-11-15
HUE062511T2 (hu) 2023-11-28
WO2017044840A1 (en) 2017-03-16
EP3347002A1 (en) 2018-07-18
CA2997376A1 (en) 2017-03-16
JP2020200352A (ja) 2020-12-17
EP3347002B1 (en) 2023-06-07
AU2016319107B2 (en) 2021-02-25
MX2022003128A (es) 2022-08-02
US11191742B2 (en) 2021-12-07
CA2997376C (en) 2024-05-14
US20220096406A1 (en) 2022-03-31
MD3347002T2 (ro) 2023-10-31
PL3347002T3 (pl) 2023-11-13
SI3347002T1 (sl) 2023-12-29
KR20220042480A (ko) 2022-04-05
HK1257874A1 (en) 2019-11-01
DK3347002T3 (da) 2023-08-14
KR102547164B1 (ko) 2023-06-22
CN116712423A (zh) 2023-09-08
KR20180051561A (ko) 2018-05-16
MX2018003023A (es) 2018-06-06
EP4275750A3 (en) 2024-01-17
HRP20230809T1 (hr) 2023-10-27
CN116712422A (zh) 2023-09-08
US20230414541A1 (en) 2023-12-28
JP2018526407A (ja) 2018-09-13
RS64481B1 (sr) 2023-09-29
JP6789579B2 (ja) 2020-11-25
ES2952727T3 (es) 2023-11-03
JP2025065545A (ja) 2025-04-17
JP7128536B2 (ja) 2022-08-31
FI3347002T3 (fi) 2023-08-10
PT3347002T (pt) 2023-07-27
SMT202300250T1 (it) 2023-09-06
MX392677B (es) 2025-03-24
CN108289870A (zh) 2018-07-17
LT3347002T (lt) 2023-09-11
AU2016319107A1 (en) 2018-03-22
EP3347002A4 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
KR102412997B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
EP2680836B1 (en) New compositions for treating neurological disorders
EP3038614B1 (en) Composition comprising torasemide and baclofen for treating neurological disorders
US11116773B2 (en) Method of treating dementia
EP3962488A1 (en) A method of treating mental, behavioral, cognitive disorders
KR20160111013A (ko) 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
US10736876B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
CN115212194A (zh) 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
HK1224182B (en) Composition comprising torasemide and baclofen for treating neurological disorders
HK1190607B (en) New compositions for treating neurological disorders
HK1190607A (en) New compositions for treating neurological disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180403

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210907

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20211119

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220124

Patent event code: PE09021S01D

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220322

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220509

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220621

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220621

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250612

Start annual number: 4

End annual number: 4